Medtronic PLC $MDT Shares Sold by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. decreased its holdings in Medtronic PLC (NYSE:MDT) by 5.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 34,122 shares of the medical technology company’s stock after selling 2,008 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Medtronic were worth $2,974,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. 1248 Management LLC acquired a new position in Medtronic during the 1st quarter valued at about $26,000. Twin Tree Management LP bought a new position in shares of Medtronic in the first quarter valued at approximately $29,000. Activest Wealth Management boosted its holdings in shares of Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares in the last quarter. Investment Management Corp VA ADV increased its stake in shares of Medtronic by 144.2% during the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 238 shares during the period. Finally, GFG Capital LLC bought a new stake in Medtronic during the second quarter worth approximately $36,000. 82.06% of the stock is currently owned by institutional investors.

Insider Transactions at Medtronic

In related news, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at $461,850. This trade represents a 100.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.26% of the company’s stock.

Medtronic Stock Up 0.3%

Shares of NYSE:MDT opened at $96.12 on Friday. The firm has a 50 day simple moving average of $94.37 and a 200 day simple moving average of $90.26. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $99.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The company has a market cap of $123.29 billion, a PE ratio of 26.48, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company’s revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on MDT. Citigroup increased their price target on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $111.00 target price on shares of Medtronic in a research note on Friday, October 10th. Wells Fargo & Company boosted their price target on shares of Medtronic from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Sunday, November 2nd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $103.06.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.